重组人甲状旁腺激素联合钙剂对绝经后骨质疏松症患者骨密度及骨代谢的影响

被引:11
作者
王苗 [1 ]
林雷 [2 ]
王贵良 [1 ]
王晓飞 [1 ]
李鹏斌 [1 ]
机构
[1] 河北省廊坊市中医院骨科
[2] 河北医科大学第一医院骨科
关键词
绝经后骨质疏松症; 重组人甲状旁腺激素; 钙剂; 骨密度; 骨代谢;
D O I
暂无
中图分类号
R580 [];
学科分类号
摘要
目的探讨重组人甲状旁腺激素联合钙剂对绝经后骨质疏松症患者骨密度及骨代谢的影响。方法选择2015年1月至2017年5月河北省廊坊市中医院及河北医科大学第一医院收治的122例绝经后骨质疏松症患者,采用随机数字表法分为对照组和研究组,每组61例。对照组采用钙剂治疗,研究组采用重组人甲状旁腺激素联合钙剂治疗,均连续治疗6个月。比较两组患者治疗前后的骨密度水平、骨代谢指标、生活质量评分及临床疗效、不良反应发生情况。结果研究组治疗总有效率为90.16%,明显高于对照组的75.41%,差异有显著性(P<0.05)。两组治疗后股骨颈、腰椎2-4、股骨大转子骨密度均较治疗前升高,且研究组高于对照组,差异有显著性(P<0.05)。两组治疗后骨源性碱性磷酸酶、Ⅰ型胶原交联C末端肽及血钙水平均较治疗前升高,且研究组高于对照组,差异有显著性(P<0.05)。两组治疗后生活质量均较治疗前改善,且研究组优于对照组,差异有显著性(P<0.05)。研究组的不良反应发生率(21.31%)与对照组(13.11%)比较差异无显著性(P>0.05)。结论重组人甲状旁腺激素联合钙剂对绝经后骨质疏松症的疗效显著,可提高骨密度并改善骨代谢,值得临床推广应用。
引用
收藏
页码:651 / 654
页数:4
相关论文
共 8 条
[1]
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors [J].
Cosman, Felicia ;
Hattersley, Gary ;
Hu, Ming-yi ;
Williams, Gregory C. ;
Fitzpatrick, Lorraine A. ;
Black, Dennis M. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (01) :17-23
[2]
Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.[J].Yang Shen;Dona L. Gray;Dorothy S. Martinez.Endocrinology and Metabolism Clinics of North America.2016, 1
[3]
Treatment needs and current options for postmenopausal osteoporosis [J].
Gennari, Luigi ;
Rotatori, Stefano ;
Bianciardi, Simone ;
Nuti, Ranuccio ;
Merlotti, Daniela .
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) :1141-1152
[4]
Osteoporosis and vascular calcification in postmenopausal women: a cross-sectional study [J].
Lampropoulos, C. E. ;
Kalamara, P. ;
Konsta, M. ;
Papaioannou, I. ;
Papadima, E. ;
Antoniou, Z. ;
Andrianopoulou, A. ;
Vlachoyiannopoulos, P. G. .
CLIMACTERIC, 2016, 19 (03) :303-307
[5]
The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: A clinical trial study.[J].Feyzi Gokosmanoglu;Ceyhun Varim;Aysegul Atmaca;Mehmet Atmaca;Ramis Colak.Journal of Research in Medical Sciences.2016, 1
[6]
Chronic lead poisoning magnifies bone detrimental effects in an ovariectomized rat model of postmenopausal osteoporosis [J].
Lee, Ching Ming ;
Romina Terrizzi, Antonela ;
Bozzini, Clarisa ;
Emilce Pineiro, Adriana ;
Ines Conti, Maria ;
Pilar Martinez, Maria .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2016, 68 (01) :47-53
[7]
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial [J].
Bone, H. G. ;
Dempster, D. W. ;
Eisman, J. A. ;
Greenspan, S. L. ;
Mcclung, M. R. ;
Nakamura, T. ;
Papapoulos, S. ;
Shih, W. J. ;
Rybak-Feiglin, A. ;
Santora, A. C. ;
Verbruggen, N. ;
Leung, A. T. ;
Lombardi, A. .
OSTEOPOROSIS INTERNATIONAL, 2015, 26 (02) :699-712
[8]
Treatment of post-menopausal osteoporosis: beyond bisphosphonates [J].
Ishtiaq, S. ;
Fogelman, I. ;
Hampson, G. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2015, 38 (01) :13-29